Table 2

Adjusted HRs of breast cancer-specific mortality associated with race (black women vs. white women)
White Black Model 1a Model 2a,b
Person-years Death (No.) Person-years Death (No.) HR 95% CI HR 95% CI
All women 6246 131 4471 141 1.54 1.21 to 1.97 1.26 0.99 to 1.62
Subtypes defined by ER/PR/HER2
 TN 1341 46 1381 57 1.21 0.81 to 1.83 1.08 0.71 to 1.64
 Luminal A 3853 56 2235 47 1.52 1.01 to 2.28 1.23 0.81 to 1.86
 Luminal B 643 16 481 14 1.67 0.67 to 4.19 0.98 0.27 to 3.58
 HER2-enriched 408 13 375 23 2.27 0.87 to 5.93 1.95 0.71 to 5.37
Subtypes defined by ER/PR/HER2/p53
 TN/p53- 825 24 664 30 1.38 0.76 to 2.51 1.32 0.70 to 2.47
 TN/p53+ 516 22 717 27 1.04 0.56 to 1.93 1.03 0.55 to 1.95
 Luminal A/p53- 3262 39 1814 33 1.50 0.92 to 2.44 1.22 0.74 to 2.04
 Luminal A/p53+ 591 17 421 14 1.10 0.40 to 2.97 0.81 0.28 to 2.39
Younger women (ages 35–49 yrs) 3066 83 2248 84 1.45 1.06 to 1.99 1.21 0.87 to 1.66
Subtypes defined by ER/PR/HER2
 TN 861 33 785 39 1.30 0.80 to 2.12 1.11 0.67 to 1.84
 Luminal A 1623 31 1069 22 1.16 0.65 to 2.05 1.01 0.56 to 1.80
Subtypes defined by ER/PR/HER2/p53
 TN/p53- 513 17 372 19 1.38 0.67 to 2.85 1.39 0.66 to 2.95
 TN/p53+ 349 16 413 20 1.14 0.56 to 2.35 1.07 0.51 to 2.25
 Luminal A/p53- 1329 23 792 12 0.86 0.41 to 1.80 0.77 0.36 to 1.63
 Luminal A/p53+ 294 8 277 10 1.04 0.23 to 4.63 0.80 0.17 to 3.72
Older women (ages 50–64 yrs) 3181 48 2223 57 1.71 1.16 to 2.53 1.38 0.93 to 2.04
Subtypes defined by ER/PR/HER2
 TN 480 13 596 18 1.00 0.47 to 2.10 1.03 0.48 to 2.20
 Luminal A 2231 25 1167 25 2.07 1.16 to 3.70 1.51 0.83 to 2.74
Subtypes defined by ER/PR/HER2/p53
 TN/p53- 313 7 292 11 1.56 0.52 to 4.67 1.34 0.41 to 4.37
 TN/p53+ 167 6 304 7 0.79 0.23 to 2.71 0.87 0.24 to 3.14
 Luminal A/p53- 1934 16 1022 21 2.53 1.27 to 5.04 1.89 0.93 to 3.86
 Luminal A/p53+ 297 9 144 4 1.16 0.31 to 4.35 0.90 0.15 to 5.48

HRs are from multivariable Cox proportional hazards regression models using age (in days) at diagnosis and at death or end of follow-up as the time scale and stratified by single years of age at diagnosis. aAdjusted for study site. bAdditionally adjusted for tumor stage. Abbreviations: HR, hazard ratio; CI, confidence interval. ER, estrogen receptor; PR, progesterone receptor; HER, human epidermal growth factor receptor; TN, triple negative. Note: TN = ER-/PR-/HER2-, Luminal A = ER+ or PR+ plus HER2-, Luminal B = ER+ or PR+ plus HER2+, HER2-enriched = ER-/PR-/HER2+.

Ma et al.

Ma et al. BMC Cancer 2013 13:225   doi:10.1186/1471-2407-13-225

Open Data